Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S, Shiwaku E, Kohno E, Fujii R, Mashimo K, Morimoto N, Yoshino M, Odaira N, Ikesue H, Hirabatake M, Takahashi K, Takahashi M, Takagi M, Nishiuma S, Ito K, Shimato A, Itakura S, Takahashi Y, Negoro Y, Shigemori M, Watanabe H, Hayasaka D, Nakao M, Tasaka M, Goto E, Kataoka N, Yokomizo A, Kobayashi A, Nakata Y, Miyake M, Hayashi Y, Yamamoto Y, Hirata T, Azuma K, Makihara K, Fukui R, Tokutome A, Yagisawa K, Honda S, Meguro Y, Suzuki S, Yamaguchi D, Miyata H, Kobayashi Y; IMBERA Investigators. Dote S, et al. Among authors: nakao m. Int J Clin Oncol. 2023 Aug;28(8):1054-1062. doi: 10.1007/s10147-023-02357-3. Epub 2023 Jun 1. Int J Clin Oncol. 2023. PMID: 37261583 Free PMC article.
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. Yanai T, et al. Among authors: nakao m. Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16. Int J Clin Oncol. 2018. PMID: 29039073 Clinical Trial.
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
Miyagi T, Tsuji D, Kawasakai Y, Ishikawa H, Tanaka R, Nakao M, Nakagaki S, Hayashi T, Ayuhara H, Harada T, Tamaki S, Maeda A, Ohashi Y, Arakawa Y, Fujita Y, Yamamoto K, Miyamoto Y, Yano T, Itoh K. Miyagi T, et al. Among authors: nakao m. Eur J Clin Pharmacol. 2023 Mar;79(3):407-414. doi: 10.1007/s00228-023-03451-1. Epub 2023 Jan 16. Eur J Clin Pharmacol. 2023. PMID: 36645467
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N. Suzuki K, et al. Among authors: nakao m. Ann Oncol. 2016 Aug;27(8):1601-6. doi: 10.1093/annonc/mdw220. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358385 Free article. Clinical Trial.
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
Hatori M, Tsuji D, Suzuki K, Yokokawa T, Kawakami K, Moriyama R, Osada-Tsuchiya M, Otake A, Nakao M, Yano T, Arakawa Y, Matsuo K, Ohashi Y, Sakata Y, Kogure Y, Tamaki S, Wada A, Taki Y, Sasahira N, Ishii H, Yamaguchi M, Itoh K. Hatori M, et al. Among authors: nakao m. Cancer. 2024 Apr 29. doi: 10.1002/cncr.35343. Online ahead of print. Cancer. 2024. PMID: 38682652
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: nakao m. Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838011 Clinical Trial.
Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.
Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K. Tsuji D, et al. Among authors: nakao m. Pharmacogenomics J. 2017 Oct;17(5):435-440. doi: 10.1038/tpj.2016.38. Epub 2016 May 31. Pharmacogenomics J. 2017. PMID: 27241063
Potentially harmful excipients in neonatal medications: a multicenter nationwide observational study in Japan.
Saito J, Nadatani N, Setoguchi M, Nakao M, Kimura H, Sameshima M, Kobayashi K, Matsumoto H, Yoshikawa N, Yokoyama T, Takahashi H, Suenaga M, Watanabe R, Imai K, Obara M, Hashimoto M, Yamamoto K, Fujiwara N, Sakata W, Nagai H, Enokihara T, Katayama S, Takahashi Y, Araki M, Iino K, Akiyama N, Katsu H, Fushimi K, Takeda T, Torimoto M, Kishi R, Mitsuya N, Kihara R, Hasegawa Y, Hamada Y, Kimura T, Wada M, Tanzawa A, Yamatani A. Saito J, et al. Among authors: nakao m. J Pharm Health Care Sci. 2021 Jul 1;7(1):23. doi: 10.1186/s40780-021-00208-9. J Pharm Health Care Sci. 2021. PMID: 34193299 Free PMC article.
2,263 results